Lingering effects of chemotherapy on mature T cells impair proliferation

Area of Science:

• Immunology
• Oncology
• Cellular Biology

Background:

• Engineered T-cell therapies show promise for hematologic malignancies.
• Transient T-cell persistence is linked to limited clinical response.
• Chemotherapy can impair T-cell suitability for adoptive cell therapy.

Purpose of the Study:

• To investigate the impact of chemotherapy on T-cell function and suitability for CAR T-cell therapy.
• To identify specific cellular deficits induced by different chemotherapy agents.
• To explore potential interventions to mitigate chemotherapy-induced T-cell damage.

Main Methods:

• In vitro analysis of T cells exposed to various chemotherapy agents (cyclophosphamide, doxorubicin, cytarabine).
• Assessment of T-cell viability, mitochondrial function, and metabolic alterations.
• Evaluation of T-cell stimulation, expansion, and chimeric antigen receptor (CAR) transduction post-chemotherapy.
• Testing the efficacy of N-acetylcysteine in reversing chemotherapy-induced deficits.

Main Results:

• Chemotherapy agents induce unique residual deficits in surviving T cells, including mitochondrial damage and metabolic alterations.
• Cyclophosphamide-induced deficits were partially reversible with N-acetylcysteine, unlike doxorubicin or cytarabine.
• Chemotherapy-exposed T cells exhibit reduced numbers and residual metabolic deficits after CAR transduction, despite preserved short-term cytolytic function.

Conclusions:

• Chemotherapy significantly impacts mature T cells, leading to lingering dysfunction that affects adoptive cell therapy manufacturing and clinical efficacy.
• Understanding these chemotherapy-induced T-cell deficits is crucial for optimizing T-cell therapy protocols.
• Targeted interventions, such as N-acetylcysteine, may hold potential for improving the quality of T cells used in therapy.